Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib

Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder characterized by the progressive accumulation of monoclonal and functionally incompetent lymphocytes; it also is the most common adult leukemia in Western countries.1 In CLL, hypogammaglobulinemia is the predominant inherent immune defect and is often further exacerbated by immunosuppressive treatment.2 Nevertheless, neither antibiotic prophylaxis nor prophylactic immunoglobulin (Ig) replacement therapy (IRT) is routinely recommended for CLL.

http://ift.tt/2ArdsaG